Global X - Genomics & Biotechnology ETF (GNOM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Global X - Genomics & Biotechnology ETF (GNOM) trades at $64.90. The Global X Genomics & Biotechnology ETF (GNOM) aims to replicate the performance of the Solactive Genomics Index, focusing on companies involved in… Market cap: $95.1M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for GNOM: GNOM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNOM against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on GNOM.
How is this calculated? →Global X - Genomics & Biotechnology ETF (GNOM) Financial Services Profile
Global X Genomics & Biotechnology ETF (GNOM) provides targeted exposure to the genomics and biotechnology sectors by mirroring the Solactive Genomics Index. With a focus on innovation in healthcare, GNOM offers investors a way to participate in the potential growth of companies involved in gene editing, personalized medicine, and other biotechnological advancements within the global asset management landscape.
What Is the Investment Thesis for GNOM?
GNOM presents an investment opportunity in the genomics and biotechnology sectors, driven by advancements in genetic research and personalized medicine. With a beta of 1.95, GNOM exhibits higher volatility compared to the broader market. The fund's performance is directly tied to the growth and innovation within the genomics and biotechnology industries. Key value drivers include breakthroughs in gene editing technologies, increasing adoption of personalized medicine, and the overall expansion of the healthcare sector. While GNOM does not offer a dividend yield, potential returns are expected through capital appreciation as the underlying companies in the Solactive Genomics Index grow and innovate. Investors may want to evaluate the risks associated with investing in a specialized sector, including regulatory hurdles, clinical trial failures, and competitive pressures.
Based on FMP financials and quantitative analysis
GNOM Key Highlights
GNOM seeks to replicate the performance of the Solactive Genomics Index, providing targeted exposure to the genomics and biotechnology sectors.
- The fund has a market capitalization of $95.1M, indicating its size within the ETF market.
- GNOM's beta of 1.95 suggests higher volatility compared to the overall market, reflecting the dynamic nature of the genomics and biotechnology industries.
- The ETF does not offer a dividend yield, focusing instead on capital appreciation through investments in growth-oriented companies.
- GNOM's investment strategy is centered on companies involved in gene sequencing, gene editing, personalized medicine, and other related biotechnological advancements.
Who Are GNOM's Competitors?
GNOM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BOAT SonicShares Global Shipping ETF | $48.40 | -0.68% | $56.6M | 50 |
| CSPF Cohen & Steers Preferred and Income Opportunities Active ETF | $26.02 | +0.00% | $48.0M | 44 |
| DEMZ Democratic Large Cap Core ETF | $47.49 | -0.25% | $67.9M | 47 |
| DVYA iShares Asia/Pacific Dividend ETF | $51.92 | +0.14% | $72.7M | 47 |
| HTEC ROBO Global Healthcare Technology and Innovation ETF | $42.56 | -1.75% | $66.3M | — |
| ASEA Global X - FTSE Southeast Asia ETF | $21.55 | +0.01% | $93.6M | 47 |
| AGNG Global X - Aging Population ETF | $38.75 | -1.11% | $88.2M | 47 |
| GESIX Lazard Global Equity Select Portfolio Institutional Shares | $19.17 | -0.14% | $79.9M | 52 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNOM's Key Strengths?
Targeted exposure to the high-growth genomics and biotechnology sectors.
- Diversification across multiple companies within the industry.
- Transparent and rules-based investment approach through index tracking.
- Potential for capital appreciation driven by innovation in healthcare.
What Are GNOM's Weaknesses?
High beta of 1.95 indicates higher volatility compared to the broader market.
- Lack of dividend yield may not appeal to income-seeking investors.
- Performance is highly dependent on the success of the genomics and biotechnology sectors.
- Subject to regulatory risks and clinical trial failures within the healthcare industry.
What Could Drive GNOM Stock Higher?
GNOM catalyst: Advancements in gene editing technologies, such as CRISPR-Cas9, are driving innovation in the treatment of genetic diseases.
- Increasing adoption of personalized medicine, driven by advancements in genetic sequencing and data analytics.
- Growing demand for innovative healthcare solutions, driven by aging populations and increasing prevalence of chronic diseases.
- Potential regulatory approvals for new gene therapies and diagnostic tools.
- Publication of positive clinical trial results for companies within the genomics and biotechnology sectors.
What Are the Key Risks for GNOM?
Insider selling — insiders were net sellers of roughly $5.4M recently.
- Regulatory hurdles and clinical trial failures can negatively impact the performance of companies within the genomics and biotechnology sectors.
- Competitive pressures from other thematic ETFs and investment funds.
- Economic downturns and market volatility can impact the value of the ETF's holdings.
- The genomics and biotechnology sectors are subject to rapid technological changes, which can render existing technologies obsolete.
- Ethical concerns surrounding gene editing and genetic engineering may lead to regulatory restrictions and public opposition.
What Are the Growth Opportunities for GNOM?
- Personalized Medicine Adoption: The increasing adoption of personalized medicine, driven by advancements in genetic sequencing and data analytics, presents a significant growth opportunity for GNOM. As healthcare providers increasingly tailor treatments to individual patients based on their genetic profiles, companies involved in personalized medicine are expected to experience substantial growth. The global personalized medicine market is projected to reach $2.4 trillion by 2032, creating a favorable environment for GNOM's portfolio companies.
- Gene Editing Technologies: Breakthroughs in gene editing technologies, such as CRISPR-Cas9, are revolutionizing the treatment of genetic diseases. Companies involved in gene editing are developing innovative therapies that have the potential to cure previously untreatable conditions. The gene editing market is projected to reach $11.87 billion by 2029, driven by increasing research and development activities and the growing prevalence of genetic disorders. GNOM's exposure to gene editing companies positions it to benefit from this growth.
- Advancements in Genetic Sequencing: The cost of genetic sequencing has decreased dramatically over the past decade, making it more accessible for research and clinical applications. This has led to a surge in genetic data, which is being used to develop new diagnostic tools and therapies. The genetic sequencing market is projected to reach $25 billion by 2027, driven by increasing demand for genetic testing and personalized medicine. GNOM's portfolio companies are at the forefront of genetic sequencing technologies, positioning the ETF to capitalize on this trend.
- Expansion of Biotechnology in Agriculture: Biotechnology is playing an increasingly important role in agriculture, with genetically modified crops being used to improve crop yields, reduce pesticide use, and enhance nutritional content. The agricultural biotechnology market is projected to reach $63.5 billion by 2027, driven by increasing demand for food and the need for sustainable agricultural practices. GNOM's exposure to companies involved in agricultural biotechnology provides diversification and growth potential.
- Increasing Healthcare Expenditure: Global healthcare expenditure is projected to continue to rise, driven by aging populations, increasing prevalence of chronic diseases, and advancements in medical technology. This trend is expected to benefit the genomics and biotechnology sectors, as healthcare providers increasingly adopt innovative diagnostic and therapeutic solutions.
What Are GNOM's Competitive Advantages?
- Specialized Focus: GNOM's focus on genomics and biotechnology provides a unique offering within the ETF market.
- Diversification: The ETF offers diversification across multiple companies within the genomics and biotechnology sectors.
- Index Tracking: GNOM's strategy of tracking the Solactive Genomics Index provides a transparent and rules-based investment approach.
- Thematic Investing: GNOM provides access to a specific investment theme, appealing to investors interested in emerging trends.
What Does GNOM Do?
The Global X Genomics & Biotechnology ETF (GNOM) was created to track the Solactive Genomics Index, offering investors a focused approach to investing in the rapidly evolving fields of genomics and biotechnology. As an exchange-traded fund (ETF), GNOM provides a diversified portfolio of companies that are at the forefront of genetic research, development, and application. This includes firms involved in gene sequencing, gene editing, personalized medicine, and other related biotechnological advancements. GNOM’s strategy is to replicate, before fees and expenses, the price and yield performance of its benchmark index. This allows investors to gain exposure to a basket of stocks representing the genomics and biotechnology sectors without the need to individually select and manage these investments. The fund’s holdings span across various market capitalizations and geographies, providing a broad representation of the genomics and biotechnology landscape. By investing in GNOM, shareholders gain access to companies that are driving innovation in healthcare and potentially transforming the way diseases are diagnosed, treated, and prevented. The ETF is managed by Global X ETFs, a well-known provider of thematic ETFs that focus on emerging trends and disruptive technologies.
What Products and Services Does GNOM Offer?
- Tracks the Solactive Genomics Index.
- Provides exposure to companies involved in genomics and biotechnology.
- Invests in firms involved in gene sequencing and gene editing.
- Offers diversification within the healthcare sector.
- Focuses on companies advancing personalized medicine.
- Replicates the index's performance before fees and expenses.
- Offers investors a way to participate in the growth of genomic technologies.
How Does GNOM Make Money?
- Generates revenue through management fees charged to investors.
- Aims to replicate the performance of the Solactive Genomics Index.
- Offers a diversified portfolio of genomics and biotechnology companies.
- Provides a cost-effective way to invest in a specialized sector.
What Industry Does GNOM Operate In?
GNOM operates within the asset management industry, specifically focusing on thematic ETFs. The genomics and biotechnology sectors are experiencing rapid growth, driven by advancements in genetic research, personalized medicine, and gene editing technologies. The competitive landscape includes other thematic ETFs and investment funds that target the healthcare and biotechnology sectors. GNOM differentiates itself by focusing specifically on genomics, offering investors a targeted approach to capitalize on the growth potential of this specialized area. The increasing demand for innovative healthcare solutions and the growing prevalence of genetic testing are driving the expansion of the genomics market.
Who Are GNOM's Key Customers?
- Individual investors seeking exposure to genomics and biotechnology.
- Institutional investors looking for thematic investment opportunities.
- Financial advisors seeking to diversify client portfolios.
- High-net-worth individuals interested in innovative healthcare technologies.
Insider Activity
The most recent 12 insider filings for Global X - Genomics & Biotechnology ETF break down as 12 sales and 0 purchases. On net that is roughly 1.8M shares disposed (about $5.4M), a signal worth weighing alongside the fundamentals.
Key Financial Metrics
Return on equity for Global X - Genomics & Biotechnology ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. GNOM trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
GNOM Valuation & Market Position
With a $95.1M market cap, Global X - Genomics & Biotechnology ETF sits in the micro-cap segment of the market.
GNOM Financials
Bull Case vs Bear Case
Bull Case
- Community sentiment has shown increasing optimism around biotech advancements, particularly in genomics, which could drive demand for this ETF.
- The ongoing innovations in gene therapy and personalized medicine are capturing investor interest, leading to a more favorable outlook for the ETF.
- Increased media coverage of biotech breakthroughs has heightened public awareness and interest, potentially attracting more investments into the ETF.
Bear Case
- Concerns over regulatory changes in the biotech sector have surfaced, leading to apprehension among investors about future growth.
- Recent bearish sentiment in social trading communities reflects worries about potential market corrections in high-growth sectors like genomics.
- Some investors are cautious due to the volatility historically associated with biotech stocks, fearing that this ETF may be impacted similarly.
- Market perception has been tempered by economic uncertainties, making investors wary of allocating funds to riskier sectors like biotechnology.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
GNOM Latest News
No recent news available for GNOM.
GNOM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNOM.
Price Targets
Wall Street price target analysis for GNOM.
GNOM MoonshotScore
What does this score mean?
The MoonshotScore rates GNOM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Global X - Genomics & Biotechnology ETF Financial Services Stock: Key Questions Answered
What does Global X - Genomics & Biotechnology ETF do?
The Global X Genomics & Biotechnology ETF (GNOM) is designed to provide investors with targeted exposure to companies involved in the genomics and biotechnology sectors. GNOM seeks to replicate the performance of the Solactive Genomics Index, investing in companies that are actively engaged in gene sequencing, gene editing, personalized medicine, and other related biotechnological advancements.
What are the main risks for GNOM?
Investing in GNOM involves several risks specific to the genomics and biotechnology sectors. Regulatory hurdles and the potential for clinical trial failures can significantly impact the performance of companies within the ETF's portfolio. The genomics and biotechnology sectors are also subject to rapid technological changes, which can render existing technologies obsolete.
How does Global X - Genomics & Biotechnology ETF make money in financial services?
Global X - Genomics & Biotechnology ETF (GNOM) generates revenue primarily through management fees charged to investors who hold shares of the ETF. These fees are calculated as a percentage of the fund's assets under management (AUM).
What are the potential benefits of investing in Global X - Genomics & Biotechnology ETF (GNOM)?
Investing in the Global X - Genomics & Biotechnology ETF (GNOM) offers several potential benefits for investors seeking exposure to the rapidly evolving fields of genomics and biotechnology. GNOM provides targeted exposure to companies involved in gene sequencing, gene editing, personalized medicine, and other related biotechnological advancements.
What are the key factors to evaluate for GNOM?
Evaluate GNOM on fundamentals, analyst consensus, and risk factors. GNOM presents an investment opportunity in the genomics and biotechnology sectors, driven by advancements in genetic research and personalized medicine. Not financial advice.
How frequently does GNOM data refresh on this page?
GNOM's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven GNOM's recent stock price performance?
Global X - Genomics & Biotechnology ETF (GNOM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Targeted exposure to the high-growth genomics and biotechnology sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GNOM overvalued or undervalued right now?
Global X - Genomics & Biotechnology ETF (GNOM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for GNOM, therefore some sections may be less detailed.
- The information provided is based on available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial goals.